長 QT 症候群治療市場 - 按類型（1 型、2 型、3 型）、治療（藥物、手術）、診斷（測試、心電圖、基因測試）、全球預測（2024 年 - 2032 年）

Long QT Syndrome Treatment Market - By Type (Type 1, Type 2, Type 3), Treatment (Medication, Surgical Procedures), Diagnosis (Tests, Electrocardiogram, Genetic Testing), Global Forecast (2024 - 2032)

出版日期: 2024年04月01日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在該領域領先公司加大研發力度的推動下，2024 年至 2032 年間，全球長 QT 症候群治療市場的複合年成長率將達到 6.8%。長 QT 症候群是一種以心律異常為特徵的心臟疾病，需要專門治療以預防危及生命的心律不整。該公司正在投資創新療法，例如新藥物配方和先進醫療設備，以滿足長 QT 症候群患者的特定需求。

例如，2023 年 8 月，Thryv Therapeutics Inc. 宣布了 WAVE 1 概念驗證臨床試驗的令人鼓舞的結果，該試驗評估了 LQT-1213 對於減少多非利特誘導的長 QT 個體的 QTcF 的作用。 LQT-1213 是一種強大的選擇性血清糖皮質激素誘導激酶 1 (SGK-1) 抑制劑，SGK-1 是與 QTc 延長相關的因素。

此外，人們越來越關注基因檢測，以確定與疾病相關的潛在基因突變。隨著對長 QT 症候群分子基礎了解的進步和標靶治療的發展，對有效治療的需求不斷增加，為改善患者治療結果帶來了希望。

長QT症候群治療行業的整體規模根據類型、治療、診斷和地區進行分類。

從2024 年到2032 年，2 型長QT 症候群將呈現出令人稱道的成長。的治療。這種亞型的患者面臨更高的危及生命的心律不整的風險，需要進行標靶治療。隨著研究的不斷進展，人們對 2 型長 QT 症候群的分子機制有了越來越多的了解，從而開發出適合其特定需求的更有效的治療方法。這導致長 QT 綜合症治療市場對專門療法的需求不斷成長。

基因檢測領域的長QT 症候群治療市場將在2024 年至2032 年實現顯著的複合年成長率。策略。基因測試可以識別這些突變，從而為患者提供標靶治療和風險分層。隨著新一代定序等基因檢測技術的進步，導致長 QT 症候群的突變的識別變得更加容易和準確。因此，長 QT 症候群治療市場對基因檢測的需求不斷成長，從而促進了更精確和客製化的患者護理方法。

歐洲長QT 症候群治療市場將在2024 年至2032 年呈現可觀的複合年成長率。和診斷。以個人化醫療為重點，歐洲醫療保健提供者正在採用創新療法和基因檢測，為個別患者量身定做治療方案。隨著醫療保健系統努力改善長 QT 症候群患者的治療結果，這導致歐洲對長 QT 症候群治療的需求不斷成長。

主要趨勢
藥物
- 依藥物類型
  - 鉀補充劑
  - BETA-受體阻斷劑
  - 鈉通道阻斷劑
- 按配銷通路
  - 醫院藥房
  - 零售藥局
  - 網路藥局
外科手術
- 按程式類型
  - 植入式心律轉復除顫器 (ICD) 放置
  - 左心交感神經去神經術（LCSD）
  - 心臟移植
- 按最終用途
  - 醫院
  - 心臟中心
  - 其他最終用戶

第 7 章：市場估計與預測：按診斷 2021 - 2032

主要趨勢
測試
心電圖
基因檢測
其他診斷類型

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott Laboratories
AstraZeneca
Bayer AG
Boehringer Ingelheim
Boston Scientific Corporation
Bristol Myers Squibb
GSK plc
Medtronic Plc
Merck & Co., Inc.
Pfizer Inc.
Sanofi

簡介目錄

Product Code: 8775

Global Long QT Syndrome Treatment Market will witness 6.8% CAGR between 2024 and 2032, driven by increased research and development efforts by leading companies in the field. Long QT Syndrome is a cardiac disorder characterized by abnormal heart rhythms, necessitating specialized treatment to prevent life-threatening arrhythmias. Companies are investing in innovative therapies, such as new drug formulations and advanced medical devices, to address the specific needs of Long QT Syndrome patients.

For instance, in August 2023, Thryv Therapeutics Inc. announced encouraging results from the WAVE 1 Proof of Concept clinical trial assessing LQT-1213 for reducing QTcF in individuals with long QT dofetilide-induced. LQT-1213 is a powerful and selective inhibitor of Serum Glucocorticoid-Inducible Kinase 1 (SGK-1), a factor associated with QTc prolongation.

Additionally, there is a growing focus on genetic testing to identify the underlying genetic mutations associated with the condition. With advancements in understanding the molecular basis of Long QT Syndrome and the development of targeted treatments, the demand for effective therapies is rising, offering hope for improved patient outcomes.

The overall Long QT Syndrome Treatment Industry size is classified based on type, treatment, diagnosis, and region.

The long QT syndrome type 2 segment will exhibit commendable growth from 2024 to 2032. Long QT Syndrome type 2, one of the subtypes of this cardiac disorder, requires specialized treatment due to its distinct genetic and physiological characteristics. Patients with this subtype face a higher risk of life-threatening arrhythmias, necessitating targeted therapies. As research continues to advance, there is a growing understanding of the molecular mechanisms underlying Long QT Syndrome type 2, leading to the development of more effective treatments tailored to its specific needs. This has resulted in a rising demand for specialized therapies in the Long QT Syndrome treatment market.

The long QT syndrome treatment market from the genetic testing segment will register a notable CAGR from 2024 to 2032. Long QT Syndrome, a genetic heart rhythm disorder, requires personalized treatment strategies based on the specific genetic mutations involved. Genetic testing allows for the identification of these mutations, enabling targeted therapies and risk stratification for patients. With advancements in genetic testing technologies, such as next-generation sequencing, the identification of Long QT Syndrome-causing mutations has become more accessible and accurate. As a result, there is a growing demand for genetic testing in the Long QT Syndrome treatment market, facilitating more precise and tailored approaches to patient care.

Europe long QT syndrome treatment market will demonstrate a decent CAGR from 2024 to 2032. European countries are increasingly investing in advanced healthcare systems, leading to greater awareness and diagnosis of rare conditions like Long QT Syndrome. With a focus on personalized medicine, European healthcare providers are adopting innovative therapies and genetic testing to tailor treatments to individual patients. This has resulted in a growing demand for Long QT Syndrome treatments in Europe as healthcare systems strive to improve outcomes for patients with this condition.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of long QT syndrome
  - 3.2.1.2 Technological advancements in treatment modalities
  - 3.2.1.3 Advancement in genetic testing and diagnosis
  - 3.2.1.4 Growing geriatric population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of surgical procedures
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Long QT syndrome type 1
5.3 Long QT syndrome type 2
5.4 Long QT syndrome type 3
5.5 Other types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Medication
- 6.2.1 By drug type
  - 6.2.1.1 Potassium supplements
  - 6.2.1.2 Beta-blockers
  - 6.2.1.3 Sodium channel blockers
- 6.2.2 By distribution channel
  - 6.2.2.1 Hospital pharmacies
  - 6.2.2.2 Retail pharmacies
  - 6.2.2.3 Online pharmacies
6.3 Surgical procedures
- 6.3.1 By procedure type
  - 6.3.1.1 Implantable cardioverter-defibrillator (ICD) placement
  - 6.3.1.2 Left cardiac sympathetic denervation (LCSD)
  - 6.3.1.3 Cardiac transplantation
- 6.3.2 By end-use
  - 6.3.2.1 Hospitals
  - 6.3.2.2 Cardiac centers
  - 6.3.2.3 Other end-users

Chapter 7 Market Estimates and Forecast, By Diagnosis 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Tests
7.3 Electrocardiogram
7.4 Genetic testing
7.5 Other diagnosis types

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East and Africa